Investing in speculative stocks (usually smaller stocks with higher betas) is always a risky venture. That's why speculative investing is a game for aggressive investors only. But with high risk comes high reward, especially when the timing is right. Here we have identified two stocks aggressive may want to consider -- one to sell and another to buy.
Dendreon (DNDN) at $12 is a stock to sell. Dedreon is a biotechnology company that develops, manufactures and sells cancer drugs. One of the company's products that have received FDA approval is Provenge, for the treatment of metastatic prostate cancer. The problem, however, is that the drug is too expensive and its benefits too limited to accept broadly. That's why the company's performance, especially its revenues, have failed to stand up to analysts expectations. The stock has been on a rough ride, trading as high as low 40s two years ago when it received FDA approval, down to low teens recently.
BioSante Pharmaceuticals (BPAX) at $0.90 is the stock to buy. BioSante Pharmaceuticals is a pharmaceutical company developing cancer treatments, especially vaccines for rare forms of cancer that have received drug designation (increase patent protection). So far, the company had several misses. That's why the stock has tumbled from $10 in 2005, down to $0.90 recently. However, the company has made progress in some areas, like the development of a pancreatic therapy that increases survival rates in early clinical trials, as reported on Monday.